AstraZeneca’s Nirsevimab: US FDA Wants Input On How It Would Fit With Pediatric RSV Vaccines

 
• By Derrick Gingery

Proposed RSV prevention treatment for infants and neonates showed efficacy with few safety concerns, but with pediatric vaccines in development, FDA wants the Antimicrobial Drugs Advisory Committee to discuss what data would be needed to determine appropriate use in vaccinated infants and mothers.

RSV Vaccine
The FDA and CDC could co-develop educational materials for nirsevimab similar to Vaccine Information Statements. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers